Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Operating Costs and Expenses:
General and administrative	$ 1,604	$ 1,218	$ 5,539	$ 4,154
Research and development	10,046	3,693	24,048	9,247
Total Operating Costs and Expenses	11,650	4,911	29,587	13,401
Loss from Operations	(11,650)	(4,911)	(29,587)	(13,401)
Other Income (Expense):
Change in fair value of warrant liability	4,141	0	(3,906)	0
Other income	0	0	0	95
Interest income	2	1	5	2
Total Other Income (Expense)	4,143	1	(3,901)	97
Net Loss	(7,507)	(4,910)	(33,488)	(13,304)
Net Loss Attributable to Non-controlling Interest	(733)	0	(733)	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$ (6,774)	$ (4,910)	$ (32,755)	$ (13,304)
Net Loss Per Share - Basic	$ (0.08)	$ (0.08)	$ (0.42)	$ (0.23)
Net Loss Per Share - Dilutive	$ (0.12)	$ (0.08)	$ (0.42)	$ (0.23)
Net Income (Loss) Per Share - Basic and Dilutive
Weighted average number of shares outstanding during the period - Basic (in shares)	85,974,751	58,453,528	77,300,375	58,356,025
Weighted average number of shares outstanding during the period - Dilutive (in shares)	87,585,103	58,453,528	77,300,375	58,356,025